Regarding these limitations and promising results from evaluating BsAbs in RA, designing novel BsAbs, targeting CCL2 and other inflammatory mediators such as TNF-α, IL-1β, and IL-17 may improve the effectiveness of immunotherapy in patients with OA in a synergistic fashion (200, 201). This evidence concerns the gene IL17A and rheumatoid arthritis.